A fully human monoclonal antibody with high affinity and neutralizing activity against human metapneumovirus and its application

By screening and optimizing fully human monoclonal antibodies against children's immune system, the difficulties in the prevention and treatment of hMPV infection in children under existing technologies have been overcome. This has enabled the development of fully human monoclonal antibodies with high affinity and high neutralizing activity, reducing the risk of immunogenicity and improving safety and efficacy.

CN123106891APending Publication Date: 2026-11-17昆明市儿童医院(云南省儿童医院)
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611339281.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-31
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technologies lack high-affinity and highly effective fully human monoclonal antibodies for children, making the prevention and treatment of hMPV infection in children difficult, and existing antibodies also pose a high risk of immunogenicity.

Method used

By screening and optimizing fully human monoclonal neutralizing antibodies against the hMPV-F antigen in children's immune systems, and combining these with in vitro antigen-antibody binding assays and viral infection neutralization assays, monoclonal antibodies with high affinity and high neutralizing activity were obtained.

Benefits of technology

It provides a fully human monoclonal antibody with high affinity and high neutralizing activity for children, reducing the risk of immunogenicity and improving the safety and efficacy of treating and preventing hMPV infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106891A_ABST
    Figure CN123106891A_ABST
Patent Text Reader

Abstract

This invention relates to a fully human monoclonal antibody with high affinity and neutralizing activity against metapneumovirus and its applications. It comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region includes amino acid sequences having complementarity-determining regions (CDR1) as shown in SEQ ID NO:1, CDR2 as shown in SEQ ID NO:2, and CDR3 as shown in SEQ ID NO:3, respectively. The light chain variable region includes amino acid sequences having CDR1 as shown in SEQ ID NO:4, CDR2 as shown in GAS, and CDR3 as shown in SEQ ID NO:5, respectively. This invention obtains a fully human monoclonal antibody with high affinity (Kd ≤ 10) by screening memory B cells from multiple positive pediatric samples and conducting numerous in vitro antigen-antibody binding experiments (EC50 binding titer and SPR affinity detection) and virus (live virus) infection neutralization experiments. ‑9 M) and highly efficient neutralizing activity (IC) 50 Monoclonal antibodies (<100 ng / mL).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of biomedicine and antibody engineering technology, specifically to a fully human monoclonal antibody (KCH-H147) with high affinity and neutralizing activity against human metapneumovirus and its applications. Background Technology

[0002] Human metapneumovirus (hMPV), belonging to the family Pneumoviridae, is the second leading cause of lower respiratory tract infections in humans after RSV. Children under 5 years old are the primary population infected with hMPV; it is estimated that over 14 million cases of acute lower respiratory tract infections and 1 in 1000 deaths in children under 5 years old are attributed to hMPV infection annually. Adult infection typically presents as asymptomatic or flu-like symptoms, which are mild or self-limiting. However, in the elderly, immunocompromised individuals, and patients with chronic diseases such as asthma or COPD, hMPV infection can cause severe bronchiolitis, asthma, and pneumonia, leading to death. Furthermore, co-infection or co-infection with other respiratory viruses (such as RSV, influenza virus, and coronavirus) or pathogens (Streptococcus pneumoniae) often results in severe clinical complications.

[0003] Currently, there are no approved preventative vaccines or specific antiviral drugs for hMPV, and clinical treatment is limited to symptomatic support such as fever reduction and fluid resuscitation. Several vaccines (such as mRNA-1653 and IVX-A12) have entered clinical trials and achieved preliminary results, but they are still some distance from being approved for market release. Monoclonal antibodies directly bind to key proteins on the surface of the virus (such as the fusion (F) protein encoded by the hMPV virus), effectively blocking the virus from entering human cells. As passive immunity, it is effective without activating the body's own immune system, which is especially important for infants with underdeveloped immune systems or patients with impaired immune function. For example, the long-acting monoclonal antibody nirsevimab, which prevents RSV, has been shown in real-world studies to reduce the risk of hospitalization for RSV in infants by approximately 80%, greatly enhancing confidence in developing a monoclonal antibody clinical drug for hMPV, a virus of the same subfamily.

[0004] As the core antigen on the surface of the hMPV virus, the F protein is the only viral antigen that induces neutralizing antibodies in this virus, because the F protein is responsible for executing a crucial and indispensable step in viral infection: the membrane fusion process of viral infection and invasion of cells. Therefore, current research and development of monoclonal antibodies against hMPV, especially neutralizing antibodies (antibodies that can block viral infection of cells), focuses on the screening and evaluation of antibodies against the F antigen.

[0005] To date, numerous publications have reported over 600 specific monoclonal antibodies obtained through screening for the hMPV virus F antigen, of which approximately 400 exhibit high, medium, and low levels of in vitro neutralizing activity. Antibody screening is achieved through three main techniques: antibody hybridoma technology, phage display technology, and single B cell antibody sorting. Hybridoma technology, the earliest and most widely used, involves fusing B cells from antigen-immunized animals (which produce antibodies but are not immortal) with myeloma cells (which can proliferate indefinitely) to form hybridoma cells. These cells can continuously secrete specific antibodies and can be passaged indefinitely. Its advantages include mature and stable technology, relatively low cost, and fewer ethical constraints. Disadvantages include long processing time (usually several months), unsuitability for screening antigens with weak toxicity or immunogenicity, and the possibility that directly obtained murine antibodies can trigger human immune responses. Phage display technology can process large quantities (up to 10...) of antibodies. 11 Human antibody gene fragments are fused with phage coat protein genes, resulting in each phage surface displaying a unique antibody fragment. Through several rounds of affinity screening involving binding, elution, and amplification, high-affinity antibodies can be screened out. The advantages are extremely high screening throughput, complete in vitro operation, and the ability to target highly toxic or weakly immunogenic targets, making it one of the methods for preparing fully human antibodies. The disadvantages are that the heavy chain (VH) and light chain (VL) of the antibody are randomly paired, sometimes affecting the antibody's native conformation and function. Additionally, the affinity of the initially obtained antibody fragment may require in vitro artificial modification (affinity maturation). Single-cell B-cell antibody technology is a relatively new technology developed in recent years. Using flow cytometry or microfluidic technology, single antigen-specific B cells are directly sorted from peripheral blood. Single-cell PCR and single-cell transcriptome analysis are then used to directly clone the naturally paired VH and VL genes from these B cells, ultimately expressing and screening for functional antibodies in vitro. The advantages are a shorter cycle compared to the previous two methods, the ability to directly obtain naturally paired antibody heavy and light chains in vivo, ensuring the native conformation and high affinity of the antibody, and making it an important technical means for fully human antibodies. The disadvantages are high requirements for equipment (such as flow cytometers and microfluidic platforms) and technical personnel, and the need for careful optimization of downstream antibody recombinant expression and screening.

[0006] Currently, monoclonal antibody drugs mainly come from three sources: animal-derived antibodies, humanized antibody drugs (including chimeric antibodies (approximately 65% ​​human) and humanized antibodies (approximately 95% human, retaining the mouse CDR region)), and fully human monoclonal antibody drugs (100% human sequence). The core advantage of fully human monoclonal antibodies over the former two is essentially that they reduce immunogenicity risk to a theoretically minimum level, while potentially offering better efficacy and safety. Minimal immunogenicity is the most fundamental advantage of fully human monoclonal antibodies. Mouse antibodies: These are recognized as foreign proteins by the human immune system, leading to the production of human anti-mouse antibodies. This rapidly neutralizes the drug, resulting in loss of efficacy and potentially triggering severe allergic reactions or even death. Therefore, mouse monoclonal antibodies have largely been phased out of the therapeutic field. Chimeric / humanized antibodies: Although significantly replaced with human sequences through genetic engineering, the remaining mouse CDR region (especially some supporting residues in the framework region) may still induce anti-drug antibodies. Once ADA (adrenergic agonist) is generated, it not only accelerates drug clearance and reduces efficacy, but in rare cases, it can also lead to serious safety issues such as thrombocytopenia. Fully human antibodies, with their gene sequences derived 100% from humans, have the lowest probability of being recognized as "self" proteins by the immune system. This significantly reduces the generation rate of ADA, thereby ensuring the sustained efficacy and safety of drugs during long-term, repeated administration. Therefore, developing fully human monoclonal antibodies is currently the mainstream approach for antibody drugs.

[0007] Currently, domestically patented monoclonal neutralizing antibodies against the hMPV-F antigen are based on hybridoma technology and single B-cell antibody technology, but all are non-fully human antibodies. Globally reported fully human monoclonal neutralizing antibodies against the hMPV-F antigen isolated from humans are over 99% derived from adults (20-40 years old) and the elderly (>55 years old). Only one foreign study reports antibodies isolated from children and infants (doi: 10.1038 / s41467-025-68021-8), while domestic literature does not report any monoclonal neutralizing antibodies against the hMPV-F antigen derived from children. It should be noted that the humoral immune levels, especially memory B-cell antibody responses, differ between healthy children and adults, influenced by development, repeated antigen exposure, and immunosenescence. In infancy (<2 months), humoral immunity is primarily provided by maternal antibodies. From early childhood to adolescence, as the immune system matures, B-cell antibodies in the GC undergo multiple rounds of somatic hypermutation and affinity selection, forming a high-affinity IgG antibody library that protects the body against exogenous infections, peaking in adulthood. However, in old age, immune function declines with age, the B-cell receptor library shrinks, and antibody diversity decreases, weakening the function of protective antibodies. Therefore, the memory B-cell antibody response against hMPV infection in children differs from that in adults. Firstly, the mutation and affinity selection of immunoglobulin (Ig) genes in young children are far lower than in adults. Secondly, repeated hMPV infections throughout the life cycle increase antibody variation. These factors contribute to a lower diversity of child-specific Ig antibody libraries and a higher convergence of antibody responses compared to adults. Furthermore, children's protein turnover rate differs from adults, potentially leading to differences in observed immunogenicity and pharmacokinetics between antibodies derived from adults and children.

[0008] Therefore, given that children, especially those under 5 years old, are the main group infected with hMPV, screening for monoclonal antibodies with the lowest immunogenicity (optimal matching results in the highest safety) in children, and further screening for monoclonal antibodies with high affinity and high neutralizing activity, is of great value for the prevention and treatment of hMPV infection in children. Summary of the Invention

[0009] Purpose of the invention In view of the problems or needs existing in the prior art, the present invention provides a fully human monoclonal antibody (e.g., KCH-H147) with high affinity and neutralizing activity against human metapneumovirus and its applications.

[0010] In summary, this invention screens and obtains specific and highly efficient monoclonal neutralizing antibodies against the hMPV-F antigen that have been optimized and selected by the child's immune system. It can obtain monoclonal antibodies with the lowest immunogenicity (optimal matching results in the highest safety) for the child population, and further screen them to obtain monoclonal antibodies with high affinity and high neutralizing activity, thereby developing anti-hMPV infection monoclonal antibody drugs for the prevention and treatment of childhood.

[0011] Solution To address the problems or needs existing in the prior art, in a first aspect, the present invention provides a monoclonal neutralizing antibody or its antigen-binding fragment (optionally a human monoclonal neutralizing antibody or its antigen-binding fragment) targeting the metapneumovirus F protein, comprising a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region comprises: three complementary determinant regions having an amino acid sequence as shown in SEQ ID NO:14; The light chain variable region comprises: three complementary determinant regions having an amino acid sequence as shown in SEQ ID NO:15; The complementary determination region of the variable region is defined by any one of the systems IMGT, Kabat, Chothia, AbM, or Contact.

[0012] Furthermore, a monoclonal neutralizing antibody or its antigen-binding fragment targeting metapneumovirus F protein is provided (optionally a human monoclonal neutralizing antibody or its antigen-binding fragment), comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: an amino acid sequence having a complementarity-determining region HCDR1 as shown in SEQ ID NO:1, a complementarity-determining region HCDR2 as shown in SEQ ID NO:2, and a complementarity-determining region HCDR3 as shown in SEQ ID NO:3, respectively; And / or, the light chain variable region comprises: an amino acid sequence having a complementarity-determining region LCDR1 as shown in SEQ ID NO:4, a complementarity-determining region LCDR2 as shown in GAS, and a complementarity-determining region LCDR3 as shown in SEQ ID NO:5, respectively.

[0013] Furthermore, the heavy chain variable region also includes frame regions H-FR1, H-FR2, H-FR3, and H-FR4 arranged in sequence interleaved with the complementarity-determining regions HCDR1, HCDR2, and HCDR3. Optionally, frame regions H-FR1, H-FR2, H-FR3, and H-FR4 are derived from human common frame sequences or human germline sequences. Optionally, the amino acid sequences of H-FR1, H-FR2, H-FR3, and H-FR4 are shown in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively. And / or, the light chain variable region further includes frame regions L-FR1, L-FR2, L-FR3 and L-FR4 arranged in sequence interleaved with complementarity-determining regions LCDR1, LCDR2 and LCDR3. Optionally, frame regions L-FR1, L-FR2, L-FR3 and L-FR4 are derived from human common frame sequences or human germline sequences. Optionally, the amino acid sequences of frame regions L-FR1, L-FR2, L-FR3 and L-FR4 are shown in SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, respectively.

[0014] As a possible embodiment, the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO:14 or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:14 or a humanized modified amino acid sequence thereof, or is composed of the same. And / or, the light chain variable region comprises, or consists of, an amino acid sequence as shown in SEQ ID NO:15, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:15, or a humanized modified amino acid sequence thereof.

[0015] As a possible embodiment, a signal peptide is also present at the N-terminus of the heavy chain variable region.

[0016] As one possible embodiment, the monoclonal antibody or its antigen-binding fragment comprises: A heavy chain comprising a heavy chain variable region and a heavy chain constant region, optionally the heavy chain constant region being derived from a portion or all of the sequence of at least one of a human antibody, a primate antibody, or a mutant thereof; optionally the heavy chain constant region comprising a portion or all of the constant region of at least one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, or a mutant thereof; optionally the heavy chain constant region is a portion or all of the constant region of IgG1; optionally the heavy chain constant region is a portion or all of the constant region of human IgG1; optionally the heavy chain comprises, or consists of, an amino acid sequence having, or having, at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with, the amino acid sequence shown in SEQ ID NO:23; and, The light chain comprises a light chain variable region and a light chain constant region. Optionally, the light chain constant region is selected from the κ-type or λ-type light chain constant region. Optionally, the light chain constant region is derived from at least one of the sequences of a human antibody, a primate antibody, or a mutant thereof. Optionally, the light chain constant region includes part or all of the CL domain. Optionally, the light chain comprises or consists of an amino acid sequence having the amino acid sequence shown in SEQ ID NO:25 or having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:25.

[0017] As a possible embodiment, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dAb, complementarity-determining region fragment, single-chain antibody, human antibody, chimeric antibody, or bispecific or multispecific antibody.

[0018] In a second aspect, a polynucleotide is provided that encodes a monoclonal neutralizing antibody or an antigen-binding fragment thereof as described in the first aspect; Optionally, the polynucleotide is a polynucleotide group, which includes: (I) A first polynucleotide comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:16, 17, and 18, respectively; optionally, comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:21; optionally, comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:24; and, (II) A second polynucleotide comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:19, ggtgcatcc, or SEQ ID NO:20, respectively; optionally, comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:22; or optionally, comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:26.

[0019] Thirdly, a biomaterial comprising the polynucleotides described in the first aspect is provided, optionally comprising: A) A nucleic acid construct comprising a polynucleotide as described in the first aspect, and optionally, further comprising at least one expression regulatory element operatively linked to the polynucleotide; B) A recombinant vector comprising the polynucleotides as described in the first aspect, or the nucleic acid constructs as described in A).

[0020] C) Transformed host cells (optionally mammalian cells, such as 293F cells) wherein the transformation involves polynucleotides as described in the first aspect, or nucleic acid constructs as described in A), or recombinant vectors as described in B).

[0021] Fourthly, a pharmaceutical composition is provided comprising the nanobody or antigen-binding fragment described in the first aspect, the polynucleotide described in the second aspect, the biomaterial described in the third aspect, and a pharmaceutically acceptable carrier and / or excipient; Optionally, the pharmaceutical composition is in the form of a nasal spray, an oral formulation, a suppository, or a parenteral formulation; Optionally, the pharmaceutical composition is a nasal spray, wherein the nasal spray is selected from aerosols, sprays, and powders; Optionally, the pharmaceutical composition is the oral formulation selected from tablets, powders, pills, granules, fine granules, soft / hard capsules, film-coated tablets, pellets, sublingual tablets, or ointments; Optionally, the pharmaceutical composition is a sublingual tablet; Optionally, the pharmaceutical composition is in the form of fine granules; Optionally, the pharmaceutical composition is a powder or granule. Optionally, the pharmaceutical composition is in the form of pellets; Optionally, the pharmaceutical composition is a parenteral preparation, which may be a transdermal preparation, ointment, plaster, topical liquid, or injectable preparation.

[0022] Fifthly, a reagent or kit for the specific detection of metapneumovirus is provided, comprising a monoclonal antibody or antigen-binding fragment thereof as described in the first aspect, a polynucleotide as described in the second aspect, or a biological material as described in the third aspect.

[0023] In a sixth aspect, the invention provides the use of the monoclonal antibody or its antigen-binding fragment described in the first aspect, the polynucleotide described in the second aspect, or the biological material described in the third aspect in the preparation of a product for the detection of metapneumovirus or metapneumovirus F protein for non-diagnostic purposes. Optionally, the metapneumovirus includes at least one of the metapneumovirus hMPV-A subtype strain and hMPV-B subtype strain.

[0024] In some preferred embodiments, the kit is a detection or diagnostic kit, wherein the monoclonal antibody or its antigen-binding fragment of the present invention contained herein further includes a detectable label; in some preferred embodiments, the kit further includes a second antibody that specifically recognizes the monoclonal antibody or its antigen-binding fragment of the present invention or an anti-idiotype antibody; preferably, the second antibody further includes a detectable label; such detectable labels are well known to those skilled in the art, including but not limited to radioactive isotopes, fluorescent substances, luminescent substances, colored substances, and enzymes (e.g., horseradish peroxidase).

[0025] In a feasible implementation, the sample is a biological sample from the subject; in a specific implementation, the sample is a nasal or oral swab sample from the subject.

[0026] This method can be used for diagnostic purposes (e.g., the sample is from a patient) or for non-diagnostic purposes (e.g., the sample is a cell sample, not from a patient).

[0027] General methods for detecting the presence or level of a target protein or antigen in a sample using monoclonal antibodies or their antigen-binding fragments are well known to those skilled in the art. In some preferred embodiments, the detection method may use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescent immunoassay, radioimmunoassay, fluorescence immunoassay, immunochromatography, competitive assays, and similar methods.

[0028] This method can be used for diagnostic purposes (e.g., the sample is from a patient) or for non-diagnostic purposes (e.g., the sample is a blood sample, not from a patient).

[0029] In a seventh aspect, the use of a monoclonal antibody or antigen-binding fragment thereof as described in the first aspect, a polynucleotide as described in the second aspect, a biological material as described in the third aspect, or a pharmaceutical composition as described in the fourth aspect in the preparation of a product for the prevention, relief, treatment, or adjunctive treatment of metapneumovirus or complications arising therefrom; Eighthly, the present invention provides a method for preventing, alleviating, treating or adjunctive treating metapneumovirus or infection with its complications, comprising administering to a patient in need an effective amount of a monoclonal antibody or antigen-binding fragment thereof as described in the first aspect above, a polynucleotide as described in the second aspect, a biological material as described in the third aspect, or a pharmaceutical composition as described in the fourth aspect.

[0030] The dosage of the active ingredient in the pharmaceutical composition of the present invention varies depending on the target patient, the target organ, symptoms, method of administration, etc. It can be determined based on the doctor's judgment, taking into account the type of dosage form, method of administration, patient's age and weight, patient's symptoms, etc.

[0031] The antibodies or antigen-binding fragments of the present invention may be administered to subjects via any suitable route of administration, including but not limited to oral, oral, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.

[0032] In a feasible implementation, the subject is a human being. The "effective dose for prevention and / or treatment" may vary depending on the recipient, the organ involved, the symptoms, the method of administration, etc., and may be determined based on the veterinarian's judgment, taking into account the type of dosage form, method of administration, the subject's age, weight, symptoms, etc.

[0033] The substance can be used alone or in combination, or in combination with other vaccines (such as other serum vaccines).

[0034] Optionally, metapneumovirus includes at least one of metapneumovirus hMPV-A subtype strain and hMPV-B subtype strain.

[0035] Beneficial effects This invention, through screening memory B cells from multiple positive pediatric samples, and conducting extensive in vitro antigen-antibody binding experiments (EC50 binding titer and SPR affinity detection) and virus (live virus) infection neutralization experiments, obtains cells with both high affinity (Kd ≤ 10⁻⁶). -9 M) and highly efficient neutralizing activity (IC) 50 Monoclonal antibodies (<100 ng / mL). Attached Figure Description

[0036] One or more embodiments are illustrated by way of example with reference to the accompanying drawings, and these illustrative examples are not intended to limit the embodiments. The term "illustrative" as used herein means "serving as an example, embodiment, or illustration." Any embodiment illustrated herein as "illustrative" is not necessarily to be construed as superior to or better than other embodiments.

[0037] Figure 1 This is a reference diagram illustrating the technical route for obtaining antibody sequences from Example 1, recombinantly expressing monoclonal antibodies, and then verifying the antibody's antigen-binding titer and antiviral protective efficacy in vitro.

[0038] Figure 2 The image shows the results of sorting individual memory B cells in F antigen-positive PBMC samples using the BD FACSArialll flow cytometer in Example 1. The top left image shows lymphocytes; the top right image shows live cells; the middle left image shows CD19-positive B cells; the middle right image shows IgG-positive B cells; the bottom left image shows memory IgG B cells; and the bottom right image shows viral F antigen-positive IgG B cells.

[0039] Figure 3 This is an electrophoresis diagram of the antibody gene sequence (heavy chain and light chain) of positive B cells amplified by nested PCR technology in Example 1. Figure 4 The eukaryotic expression vector pCMV-Rh used in Example 1 is shown.

[0040] Figure 5 The sequencing identification results are for the eukaryotic expression vector pCMV-Rh constructed in Example 1.

[0041] Figure 6 The culture supernatant from Example 1 is shown to have binding activity with F antigen ELISA.

[0042] Figure 7 This is a non-reducing gel image of the expression and purification antibody from Example 1 obtained by SD-PAGE.

[0043] Figure 8 This is an SD-PAGE reduction gel image of the expressed and purified antibody from Example 1.

[0044] Figure 9 The EC50 titer of the KCH-H147 monoclonal antibody bound to the hMPV-F protein in Example 1 was detected by ELISA.

[0045] Figure 10 Example 1 describes the detection of the affinity level between KCH-H147 monoclonal antibody and hMPV-F protein based on surface plasmon resonance (SPR) technology.

[0046] Figure 11 To test Example 1, an in vitro micro-neutralization assay was performed to determine the IC50 protection of KCH-H147 monoclonal antibody against the hMPV-A subtype virus strain (CAN97-83) infection. 50 Valence.

[0047] Figure 12 To test Example 1, an in vitro micro-neutralization assay was performed to determine the IC50 protection of KCH-H147 monoclonal antibody against the hMPV-B subtype virus strain (NL / 1 / 99) infection. 50 Valence.

[0048] Figure 13 The antibody competitive binding assay for test example 2 revealed that the KCH-H147 monoclonal antibody binds to the III antigenic epitope of the hMPV-F antigen trimer.

[0049] Figure 14 This is a protein epitope simulation diagram of the hMPV-F antigen trimer, used to show the positions of the six known antigenic epitopes Φ, I, II, III, IV, and V on the F trimer protein. Detailed Implementation

[0050] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0051] Furthermore, to better illustrate the present invention, numerous specific details are provided in the following detailed embodiments. Those skilled in the art should understand that the present invention can be practiced without certain specific details. In some embodiments, materials, elements, methods, and means well known to those skilled in the art are not described in detail in order to highlight the spirit of the invention.

[0052] Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprises" shall be understood to include the stated elements or components without excluding other elements or other components.

[0053] To facilitate a better understanding of this invention, certain technical terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, the technical terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains. For specific definitions and terms in this field, those skilled in the art may refer to Current Protocols in Molecular Biology (Ausubel). The abbreviations for amino acid residues are the standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids. The singular forms used herein (including the claims) include their corresponding plural forms unless otherwise expressly specified herein.

[0054] The term “about” when used in conjunction with a numeric value means to encompass a range of numeric values ​​having a lower limit of 5% less than the specified numeric value and an upper limit of 5% greater than the specified numeric value, including but not limited to ±5%, ±2%, ±1%, and ±0.1%, as these variations are suitable for carrying out the disclosed methods.

[0055] The term “and / or” should be understood to mean any one of the options or any combination of two or more of the options.

[0056] The term "percentage (%) sequence identity" is defined as the percentage of identical amino acid residues in a candidate amino acid sequence to a reference amino acid sequence after aligning the amino acid sequences (and, where necessary, introducing vacancies) to obtain the maximum percentage sequence identity, without considering any conserved substitutions as part of the sequence identity. Sequence alignment can be performed using various methods in the art to determine percentage amino acid sequence identity.

[0057] The term "antibody" refers to any form of antibody that has the desired biological activity. Therefore, it is used in the broadest sense and specifically includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies, and camel-derived single-domain antibodies.

[0058] The term "monoclonal antibody" refers to an antibody derived from a basic homogeneous group of antibodies, meaning that the individual antibodies comprising this group are identical except for the possibility of naturally occurring mutations, which may be present in small amounts. Monoclonal antibodies are highly specific, targeting a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically comprise a large number of antibodies targeting different epitopes (or specific to different epitopes). The modifier "monoclonal" indicates the characteristic of antibodies derived from a basic homogeneous group of antibodies and should not be construed as requiring the production of antibodies through any particular method.

[0059] In this invention, the terms "complementarity-determining region," "CDR," or "CDRs" refer to highly variable regions of the heavy and light chains of immunoglobulins, specifically regions containing one or more, or even all, of the major amino acid residues that contribute to the binding of an antibody or antigen-binding fragment to the antigen or epitope it recognizes. In specific embodiments of this invention, CDRs refer to highly variable regions of the heavy and light chains of the antibody.

[0060] In this invention, the heavy chain complementarity determination region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determination region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0061] "Antigen-binding fragments" refer to antigen-binding fragments of antibodies and antibody analogs, which typically include at least a portion of the antigen-binding region or variable region of the parent antibody, such as one or more CDRs. The antibody fragment retains at least some of the binding specificity of the parent antibody. Antigen-binding fragments include those selected from Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, biantibodies, peptides containing CDRs, etc.

[0062] The “Fab fragment” consists of a light chain, a heavy chain, CH1, and a variable region.

[0063] The “Fc” region contains two heavy chain segments that contain the CH2 and CH3 domains of the antibody. The two heavy chain segments are held together by two or more disulfide bonds and through the hydrophobic interaction of the CH3 domain.

[0064] The “Fab′ fragment” contains a light chain and a heavy chain portion that includes the VH domain, the CH1 domain, and the constant region between the CH1 and CH2 domains. Interchain disulfide bonds are formed between the two heavy chains of the two Fab′ fragments to form the F(ab′)2 molecule.

[0065] The “F(ab′)2 segment” contains two light chains and two heavy chain segments containing the VH domain, the CH1 domain, and the constant region between the CH1 and CH2 domains, thereby forming interchain disulfide bonds between the two heavy chains. Therefore, the F(ab′)2 segment consists of two Fab′ segments held together by disulfide bonds between the two heavy chains.

[0066] The “Fv region” contains variable regions from both the heavy and light chains, but lacks constant regions.

[0067] "Single-chain Fv antibody (scFv antibody)" refers to an antigen-binding fragment containing the VH and VL domains of the antibody, which are contained within a single polypeptide chain. Generally, scFv polypeptides contain a polypeptide linker between the VH and VL domains, which allows the scFv to form the desired structure for antigen binding.

[0068] A "dual antibody" is a small antigen-binding fragment with two antigen-binding sites. The fragment contains a heavy chain variable domain (VH) linked to a light chain variable domain (VL) within the same polypeptide chain (VH-VL or VL-VH). By using a linker so short as to prevent pairing between the two domains on the same chain, the domain pairs with a complementary domain of the other chain to form two antigen-binding sites.

[0069] When referring to ligand / receptor, antibody / antigen, or other binding pairs, "specific" binding means determining the presence of the protein, for example, the binding reaction of the monoclonal antibody of this invention to metapneumovirus F protein, within a heterogeneous population of proteins and / or other biological reagents. Therefore, under specified conditions, a particular ligand / antigen binds to a specific receptor / antibody and does not bind in significant amounts to other proteins present in the sample.

[0070] “Affinity” or “binding affinity” refers to the inherent binding affinity that reflects the interaction between members of a binding pair. The affinity of molecule X for its partner Y can generally be represented by the equilibrium dissociation constant (KD), which is the ratio of the dissociation rate constant to the binding rate constant (kdis and kon, respectively). Affinity can be measured by common methods known in the art. One specific method used to measure affinity is the ForteBio kinetic binding assay described herein. The term “non-binding” protein or cell means that the protein or cell does not bind, or does not bind with a high affinity, i.e., the KD of the bound protein or cell is 1.0 × 10⁻⁶ M or higher, more preferably 1.0 × 10⁻⁵ M or higher, more preferably 1.0 × 10⁻⁴ M or higher, 1.0 × 10⁻³ M or higher, more preferably 1.0 × 10⁻² M or higher.

[0071] For IgG antibodies, the term "high affinity" refers to a KD of 1.0 × 10⁻⁶ M or lower, preferably 5.0 × 10⁻⁸ M or lower, more preferably 1.0 × 10⁻⁸ M or lower, 5.0 × 10⁻⁹ M or lower, and more preferably 1.0 × 10⁻¹¹ M or lower. For other antibody subtypes, "high affinity" binding may vary. For example, for IgM subtypes, "high affinity" binding refers to a KD of 10⁻⁶ M or lower, preferably 10⁻⁷ M or lower, and more preferably 10⁻⁸ M or lower.

[0072] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless explicitly limited, the term includes nucleic acids containing analogs of known natural nucleotides that have similar binding properties to a reference nucleic acid and are metabolized in a manner similar to that of naturally occurring nucleotides (see U.S. Patent No. 8,278,036, belonging to Kariko et al., which discloses mRNA molecules in which uridine is replaced by pseudouridine, methods for synthesizing said mRNA molecules, and methods for delivering therapeutic proteins in vivo). Unless otherwise indicated, a particular nucleic acid sequence also implicitly includes variants of its conserved modifications (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, complementary sequences, and explicitly stated sequences. Specifically, degenerate codon substitution can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by a mixture of bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0073] In a first aspect, embodiments of the present invention provide a fully human monoclonal antibody with high affinity and neutralizing activity against metapneumovirus, the antibody comprising a heavy chain variable region and a light chain variable region; The heavy chain variable region includes: (I) It has three complementary determinant regions of the heavy chain variable region as shown in SEQ ID NO:14; The light chain variable region includes: (I) It has three complementary determinant regions of the light chain variable region as shown in SEQ ID NO:15; The complementary determination region of the variable region is defined by any one of the systems Kabat, Chothia, IMGT, AbM, or Contact.

[0074] It should be noted that HCDR1, HCDR2, and HCDR3 are amino acid sequences identical to those of HCDR1, HCDR2, and HCDR3 in the same heavy chain variable region defined in the antibody described in the first aspect, and LCDR1, LCDR2, and LCDR3 are amino acid sequences identical to those of LCDR1, LCDR2, and LCDR3 in the same light chain variable region defined in the antibody described in the first aspect.

[0075] For example, HCDR1, HCDR2, and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the heavy chain variable region shown in SEQ ID NO:1; LCDR1, LCDR2, and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the light chain variable region shown in SEQ ID NO:2.

[0076] In this invention, the heavy chain complementarity determination region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determination region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0077] The methods for defining CDRs are well-known in the art and include: the Kabat definition, the Chothia definition, the IMGT definition, the Contact definition, and the AbM definition. As used herein, the "Kabat definition" refers to the definition system described by Kabat et al., U.S. Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). For the "Chothia definition," see Chothia et al., J Mol Biol 196:901. 917 (1987).

[0078] Other methods of defining CDRs may not strictly follow any of the above schemes, but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or lengthened based on predictions or experimental results for specific residues or residue groups. Exemplary CDR definitions are detailed in Table 1, defined by IMGT; definitions vary slightly in different literature. Given the amino acid sequence of the variable region of an antibody, those skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods, not limited to those in Table 1, are also within the scope of this disclosure. Those skilled in the art can readily map this IMGT numbering system to any variable region sequence without relying on any experimental data outside the sequence itself.

[0079] As described in this article, "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0080] The “AbM” used has a lowercase “b” and refers to the CDR defined by Oxford Molecular’s ​​“AbM” antibody modeling software.

[0081] According to embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one or a combination of systems such as IMGT, Kabat, Chothia, AbM or Contact.

[0082] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the IMGT system.

[0083] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Kabat system.

[0084] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Chothia system.

[0085] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the AbM system.

[0086] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Contact system.

[0087] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by a combination of IMGT, Kabat, Chothia, AbM, or Contact systems.

[0088] According to embodiments of the present invention, the Kabat number positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 defined by the Kabat, Chothia, AbM or IMGT system are shown in Table 1.

[0089] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless explicitly limited, the term includes nucleic acids containing analogs of known natural nucleotides that have similar binding properties to a reference nucleic acid and are metabolized in a manner similar to that of naturally occurring nucleotides (see U.S. Patent No. 8,278,036, belonging to Kariko et al., which discloses mRNA molecules in which uridine is replaced by pseudouridine, methods for synthesizing said mRNA molecules, and methods for delivering therapeutic proteins in vivo). Unless otherwise indicated, a particular nucleic acid sequence also implicitly includes variants of its conserved modifications (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, complementary sequences, and explicitly stated sequences. Specifically, degenerate codon substitution can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by a mixture of bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0090] The reagents, enzymes, culture media, antibiotics, and milk used in the following examples of the present invention are all commercially available products. For example, the Chromium Single Cell V(D)J Reagent Kits (10X Genomics) was purchased from 10X Genomics.

[0091] Some commonly used biological materials, such as competent cells, vectors, helper phages, and cells to be transformed, are also commercially available products.

[0092] The preferred embodiments of the present invention will be described in detail below with reference to examples. It should be understood that the following embodiments are given only for illustrative purposes and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from its spirit and essence.

[0093] Information on some of the sequences involved in this invention is shown in Table 1 below, and can be commissioned to be synthesized by a biotechnology company or purchased.

[0094] The preferred embodiments of the present invention will be described in detail below with reference to examples. It should be understood that the following embodiments are given only for illustrative purposes and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from its spirit and essence.

[0095] Information on some of the sequences involved in this invention is shown in Table 1 below.

[0096] Table 1. Sequence information involved in this invention

[0097] Example 1: Preparation and purification of metapneumovirus monoclonal antibodies The implementation method in this case involves using single B-cell antibody technology to isolate memory B cells targeting the viral F antigen from the peripheral blood of children previously infected with hMPV virus. Antibody sequences are then obtained from these cells, and recombinant monoclonal antibodies are expressed for in vitro validation of the monoclonal antibody's antigen-binding titer and assessment of its antiviral protective efficacy (see technical route). Figure 1 ).

[0098] Acquisition of memory B cells from clinical hMPV-F antigen-positive samples Peripheral anticoagulated whole blood was collected from children (2-7 years old) diagnosed with hMPV virus infection and in the recovery phase after admission to our hospital. Plasma and peripheral blood mononuclear cells (PBMCs) were immediately separated after collection and stored at -80℃ and in liquid nitrogen, respectively. The F antigen IgG positive plasma samples were detected using ELISA: recombinant F antigen protein expression (Expi293 eukaryotic expression system) was plated in 96-well ELISA plates and incubated with the plasma overnight at 4℃. Anti-Human IgG (HRP) secondary antibody was used for binding, and the OD450 value was detected by colorimetric detection. Positive plasma samples corresponded to PBMCs containing F antigen-positive B cells, which were used for subsequent flow cytometry sorting of memory B cells.

[0099] Single B cell screening, antibody gene amplification, and identification based on flow cytometry 1) Flow cytometry sorting of F antigen-positive memory B cells: Phycoerythrin PE (PE Conjugation Kit - Lightning-Link, catalog number Ab102918, Abcam, UK) and allophycocyanin APC fluorescent dye (APC Conjugation Kit - Lightning-Link, catalog number Ab201907, Abcam, UK) were conjugated to F antigen protein (HMPV-F recombinant expression protein, catalog number 40993-V08H1, Beijing Yiqiao Shenzhou Technology Co., Ltd.). After removing dead cells using 7-AAD dye (catalog number APK10448-F, Beijing Yiqiao Shenzhou Technology Co., Ltd.), F antigen-positive memory B cells (F+CD19+IgG+IgM-IgD-) were sorted by flow cytometry together with CD19, IgG, IgM and IgD flow cytometry antibodies (catalog numbers 573583, 569763, 569135, 566243, BD, USA).

[0100] 2) Amplification and identification of single B-cell antibody genes After lysis of positive B cells sorted by flow cytometry, cDNA was obtained by reverse transcription using a reverse transcription kit. Using the cDNA as a template, nested PCR was performed in a progressive multi-round amplification manner, with 2-3 rounds of nested PCR using 6-8 sets of IgG primers to specifically amplify the antibody heavy chain (γ) and light chain (κ or λ) genes. The antibody genes were inserted into a T vector and a human IgG expression vector pCMV-Rh (containing the antibody leader sequence and the human IgG1 constant region sequence). First-generation sequencing was performed to identify the sequences, obtaining correctly sequenced heavy chain and light chain (κ or λ) expression plasmids (pCMV-Rh-PH, pCMV-Rh-PL-κ, and pCMV-Rh-PL-λ) for subsequent expression. The amplification primers and PCR methods followed the experimental protocols reported in Tiller T, et al. J Immunol Methods, 2008 and Liao HX, et al. J Virol Methods, 2009.

[0101] The results of single memory B cell sorting of F antigen-positive PBMC samples using the BD FACSArialll flow cytometer are as follows: Figure 2 Electrophoresis results of antibody gene sequences (heavy and light chains) amplified from positive B cells using nested PCR technology are as follows: Figure 3 And constructed into the eukaryotic expression vector pCMV-Rh (e.g. Figure 4 The sequence was confirmed to be correctly constructed after sequencing (partial results are shown below). Figure 5 ).

[0102] Antibody expression and purification 1) Antibody small-scale expression screening HEK293 cells were transiently transfected with antibody gene expression plasmid and cultured in serum-free medium in shake flasks for 3-7 days (5% CO2, 37℃, 175 rpm). The culture supernatant was then used for ELISA to detect whether the expressed antibody in the supernatant bound to the viral F antigen. Antibodies with binding activity (OD450-Blank>0.2) were screened out.

[0103] The results are as follows Figure 6 The results showed that antibodies H0126, H0135, H0147, and H0148 exhibited the best binding activity.

[0104] 2). Scale-up expression and purification of positive antibodies The previous step screened for antibodies that bind to the F antigen. HEK293 cells were then transfected and cultured. 100-200 ml of cell supernatant was harvested and centrifuged to remove cell pellet (4000 g, 30 min). The supernatant was collected and filtered through a 0.45 μM filter membrane to further remove impurities. Subsequently, the antibody was purified using affinity chromatography: the affinity chromatography column (protein A) was equilibrated with equilibration buffer, and then the culture supernatant was loaded onto the chromatography column. After loading, the target protein was eluted with elution buffer.

[0105] Concentration and purity determination: The absorbance of the purified antibody was measured using a micro-spectrophotometer at a wavelength of 280 nm. The absorbance was divided by the extinction coefficient of IgG to obtain the concentration (mg / mL) of the sample. The purity of the purified antibody was determined using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SD-PAGE). This method separates proteins in the sample based on their molecular weight in the electrophoresis gel, thus determining the purity of the inflammatory target antibody.

[0106] The monoclonal antibody with binding activity was amplified for expression and purified to obtain a monoclonal antibody with a concentration of approximately 1 mg / ml, a molecular weight of 145-153 kDa, and a purity of ≥95%. Figure 7 and Figure 8 ).

[0107] Detection of monoclonal antibody binding level and affinity to F antigen The binding levels of the purified monoclonal antibody to the F antigen were quantitatively analyzed using an ELISA method, and quantitative comparisons were performed using the half-maximal effect dose (EC50). ELISA+EC50 method: (1) Add 100ul (concentration of 1ug / ml) of hMPV-F antigen protein to an ELISA coated plate, add 8 wells for each antibody to be tested, and coat overnight at 4°C; (2) The next day, remove the coating solution from the wells, wash with 300 μL / well of PBS, then add 300 μL / well of blocking solution (PBST + 5% skim milk powder), and incubate on a shaker at room temperature for 2 hours. (3) Remove the blocking solution, wash once with 300 μL / well of PBS, and then add 100 μL / well of serially diluted monoclonal antibody solution to be tested: Dilute the antibody to be tested with antibody dilution buffer (PBST + 1% skim milk powder), starting at a concentration of 15 μg / ml, and perform 10-fold serial dilutions, for a total of 7 dilutions (15000 ng / ml, 1500 ng / ml, ..., 0.015 ng / ml). Add the different diluted antibodies to each column of wells, add PBS solution to the last well, and incubate on a shaker at room temperature for 2 hours; (4) Remove the antibody solution, wash the plate 3 times with 300ul / well PBST, wash the plate once with PBS, and then add 100ul / well HRP-anti-human IgG (A18823) secondary antibody (1:12000 dilution, PBST + 1% skim milk powder), and incubate on a shaker at room temperature for 1 hour; (5) Remove the secondary antibody solution, wash the plate 4 times with 300 μL / well PBST, wash the plate once with PBS, then add 100 μL / well TMB chromogenic solution and incubate in the dark for 10-15 min. After chromogenic development, add 100 μL / well stop solution. Read the OD450 value using a microplate reader and calculate the EC50 using Graphpad software.

[0108] Affinity assay: The affinity between the test antibody and the hMPV-F antigen protein was determined using a Biacore T200 (Cytiva) instrument. The F protein trimer was used as a ligand. The ligand was diluted to 1 μg / mL with Acetate 4.5, activated using an amino-conjugation kit on the CM5 chip, and then injected with the ligand. Finally, the chip was blocked with ethanolamine. Approximately 10⁵ RU of ligand was conjugated. The experimental buffer was 1×HBSEP buffer. The analyte, the test antibody, was serially diluted, and a negative control (0 RU) was added. The ligand-immobilized chip was bound to the analyte at a flow rate of 30 μL / min for 180 s, followed by a dissociation time of 3600 s. The chip surface was then regenerated for 30 s with Glycine 1.5 for the next cycle. The sample signal, after subtracting the negative control, was fitted using Biacore Insight Evaluation Software to obtain binding kinetics and affinity information.

[0109] Through screening, a monoclonal antibody, KCH-H147, was obtained. This monoclonal antibody exhibited an EC50 binding titer of 3.068 ng / ml to the hMPV F trimer, as shown in the results. Figure 9 .

[0110] Affinity results as Figure 10The results showed that the affinity level of the KCH-H147 monoclonal antibody was as high as 2.67 × 10⁻⁶. -11 KD(M).

[0111] Test Example 1: In vitro protective effect analysis of monoclonal antibodies Virus micro-neutralization assay to detect the in vitro protective titer of antibodies -- IC50 (half-maximal inhibitory concentration): (1) The antibody to be tested was serially diluted 3-fold with Opti-MEM medium at an initial concentration of 5 μg / ml, for a total of 7 dilutions. The diluted antibody was added to a 96-well plate, and negative controls and replicates were set up. (2) Virus addition to 96-well plates: 100 CCID50 / 50ul of virus (hMPV-A subtype strain: CAN97-83; hMPV-B subtype strain: NL / 1 / 99) was added to each well, and the reported hMPV neutralizing monoclonal antibody 101F (Más V, et al. PLoS Pathog. 2016) was used as the control antibody. A positive control for virus infection was also set up. The plates were incubated at 35°C for 1.5h. (3) Add the digested LLC-MK2 cells to the wells at a rate of 3×104 cells / 100ul / well (containing 1ug / ml TPCK trypsin and 2% penicillin antibody) and incubate at 35℃ for 5 days; (4) Remove the supernatant at the end of the culture and fix the cells with 80% ice-cold acetone; (5) Blocking: Discard the fixative, add 300 μL of blocking solution (PBST + 5% skim milk powder) to each well, and incubate on a shaker at room temperature for 2 hours; (6) Primary antibody binding: Add 100 μL of primary antibody solution (ADI61026) and incubate on a shaker at room temperature for 2 hours; (7) Secondary antibody binding: Wash 4 times with PBST solution, add secondary antibody solution (A18826), 100 μl per well, and incubate on a shaker at room temperature for 1 h; (8) Color development and reading: Remove the secondary antibody solution, wash the plate 4 times with PBST, then add TMB color development solution and incubate in the dark for 15 min. Add stop solution afterward. Read the OD450 value using a microplate reader; (9) Calculate IC50 using Graphpad software.

[0112] The results are as follows Figure 11 and Figure 12The KCH-H147 monoclonal antibody exhibits neutralizing activity IC50 values ​​of 34.09 ng / ml and 42.01 ng / ml for subtype A and subtype B viruses, respectively, both higher than the reported neutralizing activity of the anti-hMPV monoclonal antibody 101F (IC50 values ​​of 48.46 ng / ml and 219.7 ng / ml, respectively). It is a fully human monoclonal antibody with high affinity and efficient neutralization of in vitro infection with subtypes A and B of hMPV viruses.

[0113] Test Example 2: Antibody Competitive Binding ELISA Assay Monoclonal antibodies known to recognize six epitopes of the F antigen (Ø, I, II, III, IV, and V)—DS7, MPV467, MPE8, 101F, 27-14, and ADI61026 (Guo L. et al. Lancet Microbe. 2023)—were selected and used in a competitive ELISA assay to bind to the F trimer, analyzing the epitopes recognized by the candidate monoclonal antibodies. Specific steps: 384-well microplates were coated overnight with 1 μg / mL purified pre-F protein; blocked with PBST containing 5% BSA at room temperature for 2 hours. 20 μl / well of the target monoclonal antibody (concentration 10 μg / mL) was added, and incubated on a shaker at room temperature for 1 hour. Biotinylated monoclonal antibodies with known epitopes (Biotin Conjugation Kit, Abcam, ab201795) were added directly to the wells after the incubation time in the previous step. The wells were then incubated at room temperature with shaking for 1 hour. The plates were washed four times with PBST, and HRP-conjugated Streptavidin secondary antibody (SA00001-0) was added. The plates were incubated at room temperature with shaking for 1 hour. The plates were washed four times with PBST, and 25 μl / well of TMB chromogenic buffer was added. The plates were incubated at room temperature in the dark for 10-15 minutes. Finally, 100 μl of stop solution was added, and the OD450 reading was taken using a microplate reader. In the presence of unlabeled test antibodies, the binding strength of the biotinylated detection antibody is shown as a percentage of binding relative to the individual reference antibody after subtracting the background.

[0114] The results are as follows Figure 13 The results showed that the KCH-H147 monoclonal antibody binds to the III antigenic epitope of the hMPV-F antigen trimer ( Figure 14 ).

[0115] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A monoclonal neutralizing antibody or its antigen-binding fragment targeting the metapneumovirus F protein, comprising a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region includes three complementary determinant regions having an amino acid sequence as shown in SEQ ID NO:14; The light chain variable region comprises: three complementary determinant regions having an amino acid sequence as shown in SEQ ID NO:15; The complementary determination region of the variable region is defined by any one of the systems IMGT, Kabat, Chothia, AbM, or Contact.

2. A monoclonal neutralizing antibody or its antigen-binding fragment targeting the metapneumovirus F protein, comprising a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region includes an amino acid sequence having a complementarity-determining region HCDR1 as shown in SEQ ID NO:1, a complementarity-determining region HCDR2 as shown in SEQ ID NO:2, and a complementarity-determining region HCDR3 as shown in SEQ ID NO:3, respectively. And / or, the light chain variable region comprises: an amino acid sequence having a complementarity-determining region LCDR1 as shown in SEQ ID NO:4, a complementarity-determining region LCDR2 as shown in GAS, and a complementarity-determining region LCDR3 as shown in SEQ ID NO:5, respectively.

3. The monoclonal neutralizing antibody or its antigen-binding fragment as described in claim 2, characterized in that, The heavy chain variable region further includes frame regions H-FR1, H-FR2, H-FR3, and H-FR4, which are sequentially interleaved with the complementarity-determining regions HCDR1, HCDR2, and HCDR3. Optionally, frame regions H-FR1, H-FR2, H-FR3, and H-FR4 are derived from human common frame sequences or human germline sequences. Optionally, the amino acid sequences of H-FR1, H-FR2, H-FR3, and H-FR4 are shown in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively. And / or, the light chain variable region further includes frame regions L-FR1, L-FR2, L-FR3 and L-FR4 arranged in sequence interleaved with complementarity-determining regions LCDR1, LCDR2 and LCDR3. Optionally, frame regions L-FR1, L-FR2, L-FR3 and L-FR4 are derived from human common frame sequences or human germline sequences. Optionally, the amino acid sequences of frame regions L-FR1, L-FR2, L-FR3 and L-FR4 are shown in SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, respectively.

4. The monoclonal neutralizing antibody or its antigen-binding fragment as described in any one of claims 1 to 3, characterized in that, The heavy chain variable region comprises, or consists of, an amino acid sequence as shown in SEQ ID NO:14, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:14, or a humanized modified amino acid sequence thereof. And / or, the light chain variable region comprises, or consists of, an amino acid sequence as shown in SEQ ID NO:15, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:15, or a humanized modified amino acid sequence thereof.

5. The monoclonal neutralizing antibody or its antigen-binding fragment as described in any one of claims 1 to 4, characterized in that, A signal peptide is also present at the N-terminus of the heavy chain variable region; And / or, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dAb, complementarity-determining region fragment, single-chain antibody, human antibody, chimeric antibody, or bispecific or multispecific antibody.

6. The monoclonal neutralizing antibody or its antigen-binding fragment as described in any one of claims 1 to 5, wherein, The monoclonal antibody or its antigen-binding fragment comprises: A heavy chain comprising a heavy chain variable region and a heavy chain constant region, optionally the heavy chain constant region being a partial or complete sequence derived from at least one of a human antibody, a primate antibody, or a mutant thereof; optionally the heavy chain constant region comprising a partial or complete constant region of at least one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, or a mutant thereof; optionally the heavy chain constant region is a partial or complete constant region of IgG1; optionally the heavy chain constant region is a partial or complete constant region of human IgG1; optionally the heavy chain comprises, or consists of, an amino acid sequence having, or being composed of, the amino acid sequence shown in SEQ ID NO:23 or having, or being composed of, at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with, the amino acid sequence shown in SEQ ID NO:23; and, The light chain comprises a light chain variable region and a light chain constant region. Optionally, the light chain constant region is selected from the κ-type or λ-type light chain constant region. Optionally, the light chain constant region is derived from at least one of the sequences of a human antibody, a primate antibody, or a mutant thereof. Optionally, the light chain constant region includes part or all of the CL domain. Optionally, the light chain comprises or consists of an amino acid sequence having the amino acid sequence shown in SEQ ID NO:25 or having at least 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:

25.

7. A polynucleotide encoding a monoclonal neutralizing antibody or an antigen-binding fragment thereof as described in any one of claims 1 to 6; Optionally, the polynucleotide is a polynucleotide group, which includes: (I) A first polynucleotide comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:16, 17, and 18, respectively; optionally, comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:21; optionally, comprising a DNA molecule or its corresponding mRNA molecule with nucleotide sequences as shown in SEQ ID NO:24; and, (II) A second polynucleotide comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:19, ggtgcatcc, or SEQ ID NO:20, respectively; optionally, comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:22; or optionally, comprising a DNA molecule or its corresponding mRNA molecule with a nucleotide sequence as shown in SEQ ID NO:

26.

8. A biomaterial comprising the polynucleotide as described in claim 7, optionally comprising: A) A nucleic acid construct comprising the polynucleotide as described in claim 7, optionally further comprising at least one expression regulatory element operatively linked to the polynucleotide; B) A recombinant vector comprising the polynucleotide as described in claim 7, or a nucleic acid construct as described in A); C) Transformed host cells, wherein the transformation contains the polynucleotide as described in claim 7, or the nucleic acid construct as described in A), or the recombinant vector as described in B).

9. A pharmaceutical composition comprising the nanobody or antigen-binding fragment thereof as described in any one of claims 1 to 6, the polynucleotide as described in claim 7, the biomaterial as described in claim 8, and a pharmaceutically acceptable carrier and / or excipient; Optionally, the pharmaceutical composition is in the form of a nasal spray, an oral formulation, a suppository, or a parenteral formulation; Optionally, the pharmaceutical composition is a nasal spray, wherein the nasal spray is selected from aerosols, sprays, and powders; Optionally, the pharmaceutical composition is the oral formulation selected from tablets, powders, pills, granules, fine granules, soft / hard capsules, film-coated tablets, pellets, sublingual tablets, or ointments; Optionally, the pharmaceutical composition is a sublingual tablet; Optionally, the pharmaceutical composition is in the form of fine granules; Optionally, the pharmaceutical composition is a powder or granule. Optionally, the pharmaceutical composition is in the form of pellets; Optionally, the pharmaceutical composition is a parenteral preparation, which may be a transdermal preparation, ointment, plaster, topical liquid, or injectable preparation.

10. The use of a monoclonal antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6, a polynucleotide as described in claim 7, a biomaterial as described in claim 8, or a pharmaceutical composition as described in claim 9 in the preparation of a product for the prevention, relief, treatment, or adjunctive treatment of metapneumovirus or complications arising therefrom, wherein optionally, the metapneumovirus includes at least one of metapneumovirus hMPV-A subtype strains and hMPV-B subtype strains.

Citation Information

Patent Citations

  • RNA containing modified nucleosides and methods of use thereof

    US8278036B2